The National Comprehensive Cancer Network® (NCCN®) has joined 668 other patient advocacy groups, professional societies, academic institutions, medical organizations, and thousands of patients worldwide in supporting the global campaign for clinical trial registration and reporting.
NCCN®’s spokesperson, Lisa Lentz, Director of Policy and Quality, said:
“The National Comprehensive Cancer Network® supports the AllTrials campaign and its goal of clinical trial transparency. As an alliance of leading cancer centers devoted to patient care, research, and education, NCCN® believes that clinical trial registration and sharing the results of all trials can help patients and their healthcare providers make the most well-informed decisions about the treatment options that are right for them.”
NCCN® is a not-for-profit alliance in the U.S., which has 27 member institutions comprised of leading cancer centers. The alliance has been around for the past 21 years.
Lauren Quattrochi, Ph.D., Director of AllTrials USA, said:
“The cancer research community has united their voices to advocate for more transparent, evidence-based medicine to be made available for improved quality and care for all patients.”
NCCN® joins other top-tier cancer research and patient advocacy groups that recently endorsed AllTrials, including A Breath of Hope Lung Foundation, LUNGevity, the Lustgarten Foundation, Ovarian Cancer Research Fund Alliance, Mesothelioma Center, Mesothelioma Guide and the National Ovarian Cancer Coalition.
For more information or interviews please contact: Lauren Quattrochi, Ph.D., Director of AllTrials USA: email@example.com